A Randomized, Double-blind, Placebo-controlled and Multiple Dose Escalation Phase Ib Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of CM383 in Patients With Alzheimer's Disease Related Mild Cognitive Impairment and Mild Alzheimer's Disease
Latest Information Update: 09 Oct 2024
At a glance
- Drugs CM 383 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors KeyMed Biosciences
- 09 Oct 2024 New trial record